Alternative Data for Xencor
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 758 | Sign up | Sign up | Sign up |
| X Mentions | 46 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Xencor
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
| Price | $11.98 |
| Target Price | Sign up |
| Volume | 835,917 |
| Market Cap | $871M |
| Year Range | $7 - $18.14 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Xencor to Participate at Upcoming Investor ConferencesFebruary 23 - Yahoo |
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals CoverageJanuary 29 - Yahoo Entertainment |
|
|
Xencor Highlights Corporate Priorities and 2026 Pipeline MilestonesJanuary 7 - Yahoo |
 |
B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers?March 9 - Nature.com |
 |
Microbiome modulation in cancer immunotherapyMarch 8 - Nature.com |
 |
12 Health Care Stocks Moving In Tuesday's After-Market SessionFebruary 17 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 21M | 2.6M | 21M | -6M | 4.2M | -0.080 |
| Q2 '25 | 44M | 2.7M | 41M | -31M | -20M | -0.410 |
| Q1 '25 | 33M | 2.7M | 30M | -48M | -37M | -0.660 |
| Q4 '24 | 70M | 51M | 70M | -53M | -16M | -0.620 |
| Q3 '24 | 18M | 3.1M | 18M | -46M | -35M | -0.710 |
Insider Transactions View All
| Dahiyat Bassil I filed to sell 546,316 shares at $11. March 9 '26 |
| Desjarlais John R filed to sell 263,831 shares at $11. March 9 '26 |
| Eckert Celia filed to sell 76,918 shares at $11. March 9 '26 |
| Desjarlais John R filed to sell 266,333 shares at $11.2. March 9 '26 |
| Eckert Celia filed to sell 78,685 shares at $11.2. March 9 '26 |
Similar companies
Read more about Xencor (XNCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Xencor
The Market Cap of Xencor is $871M.
Currently, the price of one share of Xencor stock is $11.98.
The XNCR stock price chart above provides a comprehensive visual representation of Xencor's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Xencor shares. Our platform offers an up-to-date XNCR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Xencor (XNCR) does not offer dividends to its shareholders. Investors interested in Xencor should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Xencor are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
